Combined chemo-immunotherapy for XXXX . A monoinstitutional experience.

@entity1 @entity137 @entity2699 @entity882 @entity3012 @entity900 @entity2106 @entity1398 @entity1199 @entity204 @entity221 @entity320 @entity5713 @entity1209
UNASSIGNED: 7569 Background: The combination of Interferon a-2b (INF) and intravenous @entity1199 ( @entity1199 ) with chemotherapy (CT) has produced encouraging results in @entity320 , as shown in phase II and III trials, but @entity137 remains of concern. We report on our experience with a chemo-immunotherapy regimen with subcutaneous administration of @entity1199 . @entity1 AND METHODS: 28 @entity1 (pts) with advanced @entity320 , median age 47.5 years (range 29-70) and male/female ratio 19/9, received CT plus immunotherapy with subcutaneous @entity1199 and INF. Doses were as follows: @entity900 20 mg/m2 iv days 1-4, @entity5713 1.6 mg/m2 iv days 1-4, @entity2699 800 mg/m2 iv day 1, Interferon a-2b 5M IU/m2 sc days 1-5, @entity1199 9M IU sc days 1-5 and 8-12. Treatment was repeated every three weeks up to a maximum of six cycles. Response was assessed every two cycles and @entity137 every cycle, according to WHO and NCI criteria respectively. RESULTS: The overall response rate was 33% with 3 (11%) complete responses, lasting for 17, 14 and 24+ months respectively. There were 6 (22%) partial responses and 3 stable disease. 3 responders progressed in the central nervous system (CNS). For the whole population, median time to progression and survival were 3.5 and 9 months respectively. The most common G3-4 @entity137 was @entity1398 , reported in 25/28 (92%) pts. Only 2 pts (7%) experienced @entity221 . Less frequent was G3-4 @entity882 , observed in 6/28 (21%) pts, with only 1 pt needing platelet support. @entity1209 as well as fever following cytokine injections were reported in all pts. 1 toxic @entity204 occurred, due to @entity221 . CONCLUSIONS: This schedule with sc @entity1199 had an acceptable level of @entity137 and although the response rate was lower, @entity2106 and @entity3012 were comparable to those reported with more intensive regimens. Several pts progressed in the CNS, suggesting that new combinations able to prevent this event are needed. No significant financial relationships to disclose.
